|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because UC patients are at increased risk for developing colorectal cancer (CRC), we investigated if there was an association between SNPs in the promoter of the TNF-alpha gene and UC-CRC.
|
18289203 |
2008 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our analyses showed positive associations between proinflammatory polymorphisms at IL1RN and TNFA-307 loci and UC, as well as polymorphisms in the NOD2 gene and CD.
|
18942754 |
2009 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The frequency of allele A for TNFA rs1800629 was significantly higher in ulcerative colitis (UC) patients compared with controls (30.16 vs 16.72%; P=0.0005; odds ratio (OR)=2.15; 95% confidence interval (CI)=1.39-3.32).
|
26632999 |
2016 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As combination therapy is an emerging strategy for UC treatment, we attempt to treat established UC based on the combination of TNFα siRNA (siTNF) and IL-22.
|
30107214 |
2018 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The -308 G/A SNP in the TNF-alpha promoter is functional, and may account in part for the increased UC risk associated with the IBD3 genomic region.
|
18698679 |
2008 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this clinical differential pattern of association distinguished in two neighboring loci within the MHC region suggest an independent role of the TNF locus in the genetic susceptibility to develop UC.
|
15325795 |
2004 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Nineteen functional polymorphisms that alter the NFκB-mediated inflammatory response (TLR2 (rs3804099, rs11938228, rs1816702, rs4696480), TLR4 (rs5030728, rs1554973), TLR9 (rs187084, rs352139), LY96 (MD-2) (rs11465996), CD14 (rs2569190), MAP3K14 (NIK) (rs7222094)), TNF-α signaling (TNFA (TNF-α) (rs361525), TNFRSF1A (TNFR1) (rs4149570), TNFAIP3(A20) (rs6927172)) and other cytokines regulated by NFκB (IL1B (rs4848306), IL1RN (rs4251961), IL6 (rs10499563), IL17A (rs2275913), IFNG (rs2430561)) were associated with response to anti-TNF therapy among patients with CD, UC or both CD and UC (P ⩽ 0.05).
|
24776844 |
2014 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pooled odd ratios (ORs) and 95% confidence intervals (95% CIs) were calculated on the basis of data from 14, 18, and 7 studies from a total of 27 studies for the associations between the polymorphism of TNF-α-308 G>A and ulcerative colitis, Crohn's disease (CD) and CRC.
|
21248737 |
2011 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration.
|
30625408 |
2019 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Vedolizumab is efficacious as induction and maintenance therapy in UC patients who are naïve or refractory to tumor necrosis factor antagonists.
|
28276855 |
2017 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As part of a large, controlled, prospective study to correlate genetic markers with clinical phenotypes, tumor necrosis factor microsatellite alleles at five loci (a, b, c, d, and e) were determined from genomic DNA by polymerase chain reaction in 32 patients with a clinical and histopathologic diagnosis of ulcerative colitis who underwent ileal pouch-anal anastomosis for medically unresponsive disease.
|
10344681 |
1999 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the uncommon TNF-alpha -308 allele 2 was found to be decreased in patients with UC compared with HC (allele frequency of allele 2 in UC patients 0-15 versus 0.25 in HC, P=0.044).
|
8608636 |
1996 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No differences were noted between TNF-alpha 308 A polymorphism and clinical characteristics in UC.
|
16707968 |
2006 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the -308A allele of the TNF-alpha gene was significantly increased in both patients with CD (15%; odds ratio [OR] = 2.79; P < 0.01) and patients with UC (11%; OR = 1.96; P < 0.003) compared with controls (6%).
|
17255827 |
2007 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In patients with Crohn's disease (CD) and ulcerative colitis (UC), the use of therapeutic drug monitoring (TDM) with TNF-α antagonists has led to a personalized approach to optimize treatment and has been shown to be cost-effective.
|
29788272 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Biologic antagonists to tumor necrosis factor alpha (TNF- α) are effective medications and have become well established in the treatment of both Crohn's disease and ulcerative colitis.
|
28095262 |
2017 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α is a central mediator of intestinal inflammation in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease.
|
29286110 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that a disintegrin and metalloproteinase-17 (ADAM17), a main sheddase for tumor necrosis factor (TNF)-α, is essential for defensive epithelial properties against UC by promoting epithelial cell growth and goblet cell differentiation in mouse and human.
|
27077118 |
2016 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
BT-11 significantly decreases interferon gamma positive (IFNγ+) and tumor necrosis factor alpha positive (TNFα+) cluster of differentiation 4 positive (CD4+) T cells and increases forkhead box P3 positive (FOXP3+) CD4+ T cells in colonic lamina propria mononuclear cells from patients with CD and patients with UC at concentrations of 0.01 µM when treated ex vivo.
|
31077582 |
2020 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was lower anti-TNF use in EO-UC patients compared to AO-UC patients (5.8 vs 14.7%, p = 0.0091).
|
28884254 |
2017 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression levels of IgA and sIgA decreased, while IL-6, IL-8 and TNF-α further increased in the stress-treated UC mice (P<0.05).
|
30783488 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared to high dose corticosteroid use, anti TNF therapy is associated with less risk for death in Crohn's disease but no statistical difference in death outcomes in ulcerative colitis.
|
29535444 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because anti⁻tumor necrosis factor therapy is the mainstay for the treatment of moderate-to-severe inflammatory bowel disease; including Crohn's disease and ulcerative colitis, and because testosterone therapy in hypogonadal men with chronic inflammatory conditions reduce tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6, we suggest that testosterone therapy attenuates the inflammatory process and reduces the burden of disease by mechanisms inhibiting inflammatory cytokine expression and function.
|
30558178 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Silencing of excessive secreted tumour necrosis factor (TNF)-α from macrophages might be an effective therapy of ulcerative colitis (UC), which acquires improvements on small interfering RNA (siRNA) delivery vectors.
|
26418829 |
2016 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015).
|
29774158 |
2018 |